BioServe Expands Into New Headquarters

Beltsville, MD – Reflecting BioServe’s rapid emergence as a preferred provider for processing, developing and validating diagnostic tests, the company today announced its move to new corporate headquarters in Beltsville, Maryland. The new 40,000 sq/ft. facility combines expanded offices, state-of-the-art wet and dry laboratories and will also house the Global Repository of over 600,000 DNA, tissue and serum samples.

Over the past nine months BioServe has established itself as a company offering a complete “biomaterial to validated data” genomics solution, and is uniquely qualified to excel in the genomic diagnostics market. BioServe’s genomics solution enables partners to process vast amounts of genomic material for testing, validate genetic test markers for new diagnostics and develop new intellectual property underpinning the next generation of molecular diagnostic tests.

Recent corporate highlights include:

• The acquisition of Genomics Collaborative, a leader in facilitating biomarker discovery and validation leveraging a comprehensive library of 600,000 human DNA, tissue and serum samples linked to detailed clinical and demographic data from 140,000 consented and anonymized patients collected on four continents.

• A landmark Public Health Study in partnership with Harvard and the University of Michigan on a genetic study to understand the linkage between lead exposure and children’s intellectual development in India.

• Selected by Suracell Inc. as its testing and technology partner to build its personal genetic health and information technology businesses.

• Selected by Houston-based Specialized Clinical Center of Research (SCCOR) for a novel study aimed at identifying the genetic cause of thoracic aortic disease.

• The development of a novel serum-based diagnostic test for the identification of colorectal cancer (CRC), in collaboration with Phenomenome Discoveries Inc.

“BioServe is a company growing and evolving at a tremendous pace. We are excited to move into a world-class facility in the USA, which complements our state-of-the-art facility in India.  Our emergence into the rapidly growing personalized and predictive diagnostics space, combined with our comprehensive genomic services is creating a company uniquely positioned to lead the burgeoning field of personalized medicine," said Kevin Krenitsky, Chief Executive Officer, BioServe.